Chartmaster
2週前
A Letter from the Desk of CBIH
HOUSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings CEO Dante Picazo Addresses Cannabis Reclassification and DEA Hearings
Dear Community,
On Monday, December 2, I had the honor of representing Cannabis Bioscience International Holdings (CBIH) at the DEA Hearing Docket No. 1362 and Hearing Docket No. 24-44, focused on the reclassification of cannabis. Being chosen to speak on behalf of not only our company but also medicine, science, and patients is a privilege and a profound responsibility.
CBIH remains committed to actively participating in these hearings, which represent a crucial moment for the future of cannabis in medical and scientific advancement. The discussions include at least 20 groups, 10 in opposition and 10 in support, highlighting the intense debate surrounding this critical issue.
The proposed reclassification of cannabis from Schedule I to Schedule III could usher in transformative changes. It would pave the way for advanced research, facilitate the development of safe and effective treatments for chronic and hard-to-treat conditions, and significantly improve the quality of life for patients. Beyond medicine, this change could drive economic growth by creating jobs, attracting investment, supporting small businesses, and providing a boost to the national economy.
This is a once-in-a-lifetime opportunity, and we must recognize its magnitude. If the reclassification effort does not succeed, we may not have another chance to revisit this discussion for another 8–10 years. That is why I am calling on all stakeholders, patients willing to share their stories, especially those with multiple sclerosis and epilepsy who have found relief through medical cannabis, medical experts who can validate cannabis’s therapeutic benefits, and legal professionals equipped to navigate this complex process, to join us in this crucial mission and participate as one of CBIH’s expert witnesses in the next DEA Hearing.
Time is of the essence. We have just a narrow window to act, with a deadline of Wednesday, December 11, at 5:00 PM CT, to assemble our team of contributors. Over the next three months, we will require robust legal and scientific support to counter significant opposition, including government testimony and representation from major law firms. The expertise and participation of people who understand the necessity of this reclassification can make a meaningful difference in ensuring that we advocate effectively for this vital cause.
If you are a scientist, medical expert, patient, or legal professional and wish to contribute to this effort, please contact us via email at ir@cbih.net.
The reclassification of cannabis is more than a policy change, it is an opportunity to revolutionize quality of life, stimulate economic growth, and open doors to innovation. Please keep in mind that if Americans want cannabis to be reclassified from Schedule I to III, we are going to have to fight for it.
Thank you for your support.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://www.globenewswire.com/newsroom/ti?nf=OTMxNTg3MiM2NjI3ODQ1IzIyOTIzMDQ=
https://ml.globenewswire.com/media/MjMzODRjZjMtMmMxNS00MGY1LWIzY2UtNjk4NjFkNDdlZmVlLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3069453
Chartmaster
1月前
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical cannabinoid products.
These initiatives are driven by CBIH's commitment to enhancing quality of life for individuals facing chronic, degenerative, and life-threatening illnesses. Moreover, the company aims to lead the future of medicine by developing innovative solutions such as mRNA vaccines for cancer and other prevalent diseases that are transforming modern medicine.
“Our mission goes beyond innovation: we aim to revolutionize the pharmaceutical industry with personalized, accessible treatments designed to significantly improve patients' quality of life. By focusing on molecular biology, nuclear medicine, genetics, and advanced technologies such as nanotechnology, picotechnology and femtotechnology, we are creating highly targeted cannabinoid-based drugs that meet the unique needs of a broader spectrum of patients,” says Rosangel Andrades, CBIH R&D Director.
As we near our product launch and continue to submit medical patents (13) to the USPTO, CBIH remains focused on strengthening our team to advance production and drive innovative research. Our goal is to position the company as an attractive partner for larger pharmaceutical firms, fostering opportunities for strategic alliances. We aim to lead the way in transformative therapeutic solutions using scientifically validated medical cannabinoids, capitalizing on the coming opportunities arising from the possible reclassification of cannabis from Schedule I to Schedule III.
Under the leadership of Dr. Andrades, our R&D division has expanded significantly, enhancing our expertise and specialized teams to drive CBIH's accelerated growth. This enhanced talent pool empowers us to establish a sustainable product sales pipeline while maintaining the highest scientific and clinical standards.
Our R&D team is proud to include Dr. Stephanie Hartmann, M.D., and Dr. Yesiree Baptista, M.D., both distinguished medical practitioners and Principal Investigators in Cannabinoid Therapies. We are also supported by Dr. Jennifer Salgueiro, Ph.D. in Microbiology, and Dr. Nancy Duarte, Ph.D. in Biology and Immunology, whose molecular science expertise is instrumental in identifying new therapeutic targets within cannabinoid research. Additionally, our formulation department is reinforced by Dr. Laura Reina, Formulation Pharmacist, Dr. Ana María Maldonado, Ph.D. in Pharmacy, and Dr. Angélica Clavijo, Master in Process Design and Management, MBA, who bring invaluable expertise to our team.
"With a team of highly qualified professionals, the company is committed to addressing critical challenges such as mental health disorders. Recognizing that these conditions can profoundly impact individuals across all demographics and acknowledging the limited efficacy and accessibility of current treatment options, we strive to pioneer innovative, science-based solutions and to expand the therapeutic landscape to those in need,” says Brian Cuban, CBIH Advisory Director.
By fortifying its team with distinguished professionals, CBIH is strategically positioned to lead in the medical cannabis retail market and reinforce its role as a pioneer in scientific and medical research. With a deep commitment to advancing cannabinoid chemistry and innovative health solutions, CBIH aims to become a dominant force in the medical cannabis industry and the premier choice in national retailers.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://www.globenewswire.com/newsroom/ti?nf=OTI3NTE5MyM2NTg2OTI3IzIyOTIzMDQ=
https://ml.globenewswire.com/media/ZjYzNTdkZjctZjY2NC00ZTQ4LTliNmUtOGJiYTEzYTFlODcwLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3050173
Chartmaster
2月前
CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - November 4, 2024) - Cannabis Bioscience International Holdings (OTC Pink: CBIH) is thrilled to announce the appointment of Mr. Charles Tamburello as a new member of the board of directors. His extensive experience in the public markets, which spans nearly three decades, will play a crucial role in driving the company's mergers and acquisitions (M&A) strategy forward.
Mr. Tamburello has been instrumental in the success of hundreds of public and private companies since 1995, leveraging his deep industry knowledge and valuable connections to facilitate growth and expansion. His track record of orchestrating successful M&A transactions aligns perfectly with CBIH's strategic goals as we look to enhance our capabilities and reach. He is the owner operator of Global Discovery Group, a dynamic platform designed to facilitate engagement between public companies and the investment community, which offers a highly effective and time-efficient way for companies to showcase their latest developments, new products, services, and significant announcements.
"Recognizing the challenges ahead as we strive to reach our ambitious benchmarks, we are committed to bringing on top-tier talent and strategic guidance. Mr. Tamburello exemplifies this commitment," said John Jones, CBIH Treasurer and Director. "His extensive experience in capital acquisition and expertise in navigating complex industries will provide our shareholders with confidence that we are positioned for sustainable growth and value creation."
Charles Tamburello expressed his enthusiasm about joining CBIH, stating, "I'm excited to be a part of the vision of Cannabis Bioscience International and the journey of helping everyday people throughout the world, conquer debilitating ailments and improve their lives."
Mr. Tamburello's appointment to the CBIH board significantly strengthens the company's potential for successful mergers and acquisitions (M&A). His extensive background in executing M&A transactions across diverse sectors equips CBIH with the strategic insights and negotiation skills necessary to identify high-value acquisition targets and maximize deal success. Tamburello's deep industry connections and leadership of The Emerging Growth Conference provide CBIH with enhanced access to potential partners and acquisition opportunities, increasing the likelihood of securing advantageous deals that align with CBIH's growth objectives.
Furthermore, his expertise in capital raising allows CBIH to pursue acquisitions more aggressively, ensuring the company has the necessary resources to act swiftly on opportunities and expand its portfolio. This combination of M&A experience, industry influence, and capital acquisition skills provides CBIH with a competitive edge, enabling the company to grow strategically through targeted acquisitions that bolster its market position and drive long-term shareholder value.
This powerful combination of skills and connections positions CBIH to seize high-value opportunities and strategically expand our portfolio, strengthening our market position and delivering sustained value for shareholders. With Mr. Tamburello's leadership, we are more confident than ever in our path to becoming an industry leader and achieving long-term, transformative growth.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
https://images.newsfilecorp.com/files/10188/228741_2ab2feab447cd92f_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228741
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/228741/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=3034183
Chartmaster
5月前
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
GLOBENEWSWIRE 6:00 AM ET 7/15/2024
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings(CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range.
Preparations are underway for the production and distribution of our products, and continue to foster revenue expansion, which could only be achieved through the practical application of the skills and experiences gained over the past 15 years. Therefore, we are now navigating the licensing phase for our manufacturing units. This involves securing permissions for the production, manufacture and provision of cannabinoid-based items.
Moreover, our firm is deeply invested in maintaining the highest standards of regulatory compliance. In pursuit of this goal, the company has diligently applied for licenses required under Texas state laws, including the Retail Hemp Registration (#8305) from the Texas Department of State Health Services (DSHS), alongside the Initial Food Manufacturer License (#1037264) and Initial Food & Drug Owner application (#1037264).
Amidst ongoing project development and meticulous refinement of patent applications for our formulations and preparing for the development of clinical data trials aimed at validating our products effectiveness, CBIH remains focused on introducing novel revenue-generating avenues through dietary supplements and nutraceuticals. Through a potential strategic alliance with a distinguished national product manufacturer, CBIH looks forward to launching its cannabis-based products to the market for the first time.
"The cannabis industry has encountered major hurdles due to unclear regulations, leading to difficulties for several companies in this sector. Hence, we feel immense pride in our capacity to have been able to withstand the test of time, showcasing our resilience as CBIH seeks to gain a considerable segment of the market and ultimately achieve our pioneering goals. These initiatives collectively function as preparatory measures in light of the prospect of cannabis being reclassified as medicine, propelled by CBIH's competitive drive to spearhead the utilization of this groundbreaking shift," remarks John Jones, CBIH Treasurer and Board Director.
“This has been a journey in the making, and with the successful application of our licenses, we remain committed to strictly adhering to both federal and state regulations and the essence of the law. Our focus is on developing our products as vitamins or nutraceuticals, acknowledging the undeniable therapeutic advantages of cannabis as a form of medicine. At the core of our mission, if our products can offer healing or significantly improve the quality of life for patients, the legality surrounding medical claims becomes secondary. What matters most is harnessing the potential of cannabis compounds to aid those that traditional medicine has forgotten. It is about non-traditional medicine in a traditional world,” says Rosangel Andrades, Research and Development Director.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
Image: https://www.globenewswire.com/newsroom/ti?nf=OTE3NzYwMyM2MzY2MDgzIzIyOTIzMDQ=
Image: https://ml.globenewswire.com/media/NzBhZjhkZGMtNzJjZi00MjM4LWE2MTItZTExZDVlYjNlZGQzLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Image: Primary Logo
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.(CBIH)
Chartmaster
6月前
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
Newsfile Corp.
Newsfile Corp
A letter from our desk
Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications.
From our desks - Rosangel Andrades and Jennifer Salguero.
In the realm of medicine, patent requirements diverge from other forms of intellectual property, as clinical trials or studies are required to substantiate the attributes assigned to a compound.
While CBIH excels in bringing scientific rigor to the table, we acknowledge the imperative need for self-conducted studies. Our strategy unfolds in two primary directions. Initially, to amass comprehensive clinical evidence for our therapeutic interventions. Subsequently, to seize the opportunity presented by the impending declassification of cannabis, making clinical trials a focal point for numerous institutions and pharmaceutical entities. As we brace for the unfolding opportunities post-declassification, CBIH is strategically positioned to lead, thanks to our unique expertise as one of the limited clinical research units specializing exclusively in cannabis, thus, allowing us to generate additional revenues. This distinction would set us apart, given the scarcity of CRUs with comparable experience and understanding of cannabis clinical trials.
Moreover, we advocate for the utilization of provisional patents, which offer a 12-month grace period for conducting the requisite trials. These trials can encompass a variety of methodologies, including in vivo and in vitro preclinical studies, animal model testing, or leveraging single-cell studies.
For more information on single cells studies, please visit: drive.google.com/file/d/1yuCVocWQqq1B6EqN1G5jlzy8g8LGuQSC/view?usp=sharing
Furthermore, we intend to file all our patents with the United States Patent and Trademark Office (USPTO), targeting the lucrative U.S. market. This strategic filing not only strengthens our presence in the industry but also paves the way for collaborations with pharmaceutical companies exploring the potential of cannabinoid compounds. Our patent assets are poised to become a significant source of revenue. It's noteworthy that a 2019 Statista report indicated AbbVie's dominance with 59 cannabis patents, compared to Pfizer's 25. Given Pfizer's track record of striving for industry leadership, it's conceivable that they would be motivated to acquire more cannabis patents to assert their dominance in this emerging field.
In consequence, our objective is to tackle diseases that have been consistently overlooked and face a scarcity of effective treatments, such as menopause syndrome that could affect quite literally any woman in their lifespan, and Ewing cancer which is a severe and devastating condition that affects bones and soft tissue in adolescents. Our team is committed to addressing those neglected by conventional medical research.
From my desk - John Jones.
Evaluating our company's worth was a crucial move for our company, especially in light of potential merger and acquisition discussions. Identifying the right partner for such a significant endeavor remains our priority. Our goal transcends mere transactions; we seek a mutually beneficial partnership that thrives over time, making the selection of the perfect collaborator our greatest challenge. Moreover, achieving a valuation of $2 billion is no small feat, it is a testament to the hard work, dedication, and innovative spirit of our team.
Our agreement with VITA Biotech Research has facilitated the receipt of the second installment of $50,000 for CBIH, catalyzing advancements in the marketing and development of our nutraceuticals.
Additionally, this partnership has facilitated our ability to register trademarks for our product names, which will be sold as dietary supplements, nutraceuticals, or vitamins, adhering to local regulations. This strategic move holds significant value for our company, as certain vitamins, such as our Cancer VITA or Precancer VITA, could exert a remarkable influence if they gain distribution through retailers like Walmart or Walgreens. This highlights the critical importance of differentiating our products from those of competitors by trademarks.
Initiatives like this infuse the company with a fresh and profound value. Conversely, a firm that disregards patenting, omits trademarking, dismisses valuation, and fails to form elite distributor partnerships essentially loses its worth. Therefore, every step taken, every seed planted, dramatically elevates the company's value.
As CBIH continues to expand, we remain committed to investing time, effort, and thoughtful consideration into our endeavors that ultimately transform into revenues, predominantly because we cannot be a company that can't see the forest from the tree. Instead, we are gaining sustainable competitive advantage in the industry.
Each step we undertake lays the groundwork for future successes, mirroring the trajectory of companies that have transformed from modest beginnings to industry leaders. We are poised for a prosperous future, driven by various revenue generation centers, strategic partnerships, and continued growth.
FORWARD-LOOKING STATEMENTSThis press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://images.newsfilecorp.com/files/10188/215666_012882b504f37b28_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215666
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/215666/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2910920
Chartmaster
6月前
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers
HOUSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration.
Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic cancers. These conditions, affecting millions globally, present unique challenges due to their prevalence and the severity of their outcomes. Breast cancer, for instance, impacts approximately one in eight women in the United States over their lifetime, while pancreatic cancer is notorious for its late-stage diagnosis and grim prognosis, with a five-year survival rate below 10%.
Jennifer Salguero, PhD in Science with emphasis on Microbiology, highlights the urgency and strategic focus of our approach: "Given the stark statistics associated with these cancers, our team recognizes the critical need for aggressive yet targeted interventions. Our aim is to not only target the tumors but also safeguard surrounding tissues, leveraging the inherent antitumor properties of cannabinoids."
CBIH aims to accelerate our pace of innovation by submitting an additional 3 to 4 patents per month throughout the remainder of the year. Among our top priorities are patents related to the treatment of herpes zoster, knee osteoarthritis, and Alzheimer's disease, harnessing the antiviral, anti-inflammatory, and neuroprotective benefits of cannabinoids.
To support this goal, we are expanding and strengthening our research team, focusing on patent and formulation development. We are honored to welcome Sheila Tarqui, with a comprehensive background in biology, pharmaceutical chemistry, public health, and dermatic cosmetics, enriched by her education from Ricardo Palma University, María Auxiliadora University, San Juan Bautista Private University (Peru), and Francisco de Vitoria University (Madrid, España), makes her an invaluable addition. We expect Tarqui’s expertise will significantly contribute to advancing our innovation and maintaining our high standards of excellence.
Moreover, we are proactively trying to recruit medical specialists in oncology and cardiology to deepen our exploration of cannabis compounds' therapeutic applications. Despite substantial existing research, cardiovascular diseases persist as the world's leading cause of death, with limited understanding of cannabinoids' potential in this field. Identifying this as an emerging opportunity, we see the combination of cardiovascular medicine and cannabinoid research as a promising path for developing innovative treatments. Our recruitment efforts aim to fill this knowledge gap and unlock new possibilities for addressing prevalent and life-threatening conditions worldwide.
"These strategies contribute to securing and protecting our intellectual property which is paramount. By harnessing cutting-edge therapies, artificial intelligence, and advanced biotechnological techniques, we aim to safeguard and successfully market our groundbreaking medical advancements" says Rosangel Andrades, Research and Development Department Director.
We remain steadfast in our mission to leverage the full potential of cannabinoids to improve patient outcomes and contribute to global health initiatives. At CBIH, we are redefining medicine and treatment strategies.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://www.globenewswire.com/newsroom/ti?nf=OTE3MTQzNCM2MzQ4NzkyIzIyOTIzMDQ=
https://ml.globenewswire.com/media/NjJhZDk4NzYtYmVhMy00ODZhLTk5NTQtNGQ2OTIyOTRkYTA2LTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2905906
Chartmaster
6月前
CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California.
StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's capacity for sustained growth and expansion.
The valuation was reached through a comprehensive review of CBIH's financial metrics, market penetration, industry competition, and strategic planning. Additionally, it took into account the exceptional skill sets within the company. Including securities attorney; corporate attorney, patent attorney, in-house counsel, comptroller with a Magister Scientiarum in Administration, CPA, PCAOB, graphic designer, Master's Degree in Audiovisual Communication and Advertising Content, Ph.D.-level scientists with emphasis on microbiology, medical professionals certified in cancer biology, peritoneal dialysis, pregnancy-related emergency care, as well as board-certified in General medicine and internal medicine, Anti-aging medicine Specialist, Master of Health Care Administration, and Doctorate in Dental Surgery. These experts have contributed to the development of a diversified portfolio of innovative therapies and medical solutions over the past 15 years. Their work addresses gaps in conventional treatments, and provides natural alternatives for widespread health issues globally.
StoneBridge Advisory employed meticulous due diligence and sophisticated financial modeling during the valuation process to guarantee precision and accurately represent the value of CBIH.
John Jones, Treasurer and Director of CBIH, commented on the significance of this valuation, stating: "We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we've identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth." He further noted, "Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders."
This landmark $2 Billion valuation positions CBIH among an elite group of startups and fresher/emerging companies that have achieved such a notable feat. This milestone paves the way for CBIH to pursue strategic alliances, investment opportunities, and ambitious expansion strategies, further cementing its status as a leader in the cannabis bioscience sector.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://images.newsfilecorp.com/files/10188/213088_b92b11ca44633888_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213088
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/213088/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2892259
Chartmaster
7月前
Vita Biotech Retains CBIH Services for Clinical Studies
Newsfile Corp.
Newsfile Corp
Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the clinical data collection efforts of CBIH's rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity.
Through this strategic alliance, Vita Biotech will act as a financial subsidiary and catalyst for CBIH's data collection trials, a vital phase in evaluating the efficacy and safety of its formulations before they reach the market. This accelerated funding is expected to speed up CBIH's progress toward its scientific and commercial goals.
Furthermore, this collaboration allows CBIH to chart a course of its reconstruction process as it facilitates to isolate each medical formulation into a unique legal entity. This risk management strategy aligns with industry practices aimed at simplifying financing and partnerships, streamlining intellectual property and licensing processes.
The choice of Texas as the jurisdiction for patent housing is driven by its business-friendly environment, including favorable judicial precedents, cost-effective litigation, and access to federal courts adept in handling complex cases. Therefore, this calculated maneuver would place CBIH in a strong defensive posture in the event of legal challenges, and it is foreseen to lessen potential legal liabilities of the parent corporation.
The decision to proceed with this collaboration followed medical legal standards to mitigate any potential medical conflicts arising from the studies, upholding ethical standards to maintain credibility and executing CBIH's protocols effectively, which could lead to improved statistical significance.
"The nature of clinical trials and data collection necessitates a cooperative endeavor between different entities, each bringing unique advantages to the table, without compromising the integrity and safety of data management during the trials. This way we take a significant leap forward in both organizations' missions and the enhancement of patient care," says Dr. Jennifer Salguero, PhD in Science specialized in Microbiology from São Paulo Brazil University, and VITA's Director of Clinical Trial Operations.
Overall, this partnership offers a platform for funding CBIH's projects, safeguards both parties from risks related to intellectual property and litigation, and ensures the meticulous and ethical collection of data. CBIH and Vita Biotech look forward to potentially bolster the credibility of our research among leading pharmaceutical companies, paving the way as pioneers in medical cannabis clinical research.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstockInstagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://images.newsfilecorp.com/files/10188/211751_687e9dd4b440484c_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211751
SOURCE Cannabis Bioscience International Holdings
https://api.newsfilecorp.com/newsinfo/211751/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2882133
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
mrfumbles
3月前
Rainer
6月前
HNDRXX
6月前
okwife
6月前
EyeInTheSky
6月前
Demogod1
6月前
Nikodemos
7月前
